Pharmaceutical giant acquires biopharmaceutical researcher in move to diversify beyond current blockbuster drugs. Schering-Plough shares soar 14 percent; Merck dips 7.7 percent.
|
The drug giant stops courting states to pass laws that would require adolescent girls get the company’s cervical cancer vaccine.
|
Large-scale trial hopes to produce an immune response.
|
Nastech’s nasal obesity spray looks good in phase 1.
|
Indian firm receives U.S. approval to market Simvastatin, a rival to Merck’s Zocor.
|
Indian drug company receives funds to develop diabetes drug from German giant.
|
But Galvus disappoints when compared with generics.
|
Generic drug makers get to keep 180-day exclusivity when the FDA de-lists patents.
|
Arcoxia is easy on the stomach, but it’s tough on the heart.
|
Experimental cholesterol drug reduces LDL by 62 percent.
|
Pharma giant pays hefty premium for biotech firm to get into growing RNAi market.
|
Drug maker hit hard in Q3 as rival launches generic blood thinner.
|
Country pledges $1 million in initial financing for clinical research centers.
|
Tests of pramlintide move to Phase 3.
|
Bermuda transactions save big pharma company as much as $1.5 billion.
|
Also: Rings Director to Create Halo Games... Zeta-Jones Dumped?
|
The Merck subsidiary has yeast that can copy human cell chemistry.
|
British researchers find that an Abbott drug could also stop a virus that causes cancer.
|
Bill and Melinda Gates call for better tools to help women.
|
Expansion Capital Partners closes second cleantech fund at more than $55 million.
|
Page
1
of
5
|